Monsanto expected to raise bid for Syngenta as competing offer appears imminent

Monsanto Co., and its advisers are working flat out to accommodate Syngenta’s qualms about regulatory hurdles to a deal whose perils may well outweigh the rewards.

Investment bankers and analysts expect Monsanto to increase its bid by about 10 percent, to just short of 500 SFr, while others say Monsanto cannot afford to be scorned by the target again and would be ready to offer potentially close to 550 SFr.

But chances that antitrust regulators will block the deal remain high since the combined entity would control more of 40 percent of the U.S. seeds market.

“The deal may not happen,” said a source close to Syngenta, speaking on condition of anonymity.

He mentioned growing scepticism among Syngenta’s board that antitrust hurdles could be overcome.

Driven by regulatory concerns, Monsanto said on May 20 it would make the deal “really clean” and “really easy to get done,” in the words of the U.S. group’s Chief Operating Officer Brett Begemann, by selling Syngenta’s entire seeds business and certain crop chemical assets.

Yet the deal is anything but easy.

Sources said Monsanto has recently made changes to its team of external legal advisers in an effort to win Syngenta’s support, which it needs to follow the deal through.

Antitrust advisers of both companies have met twice in New York, the most recent a week ago, a person familiar with the matter said, but it remains unclear whether there has been any agreement.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis. Read full, original post: DEALTALK-Monsanto plots pricey Syngenta comeback amid growing skepticism

{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosate—the world's most heavily-used herbicide—pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

ChatGPT-Image-Jun-30-2026-01_09_47-PM
Viewpoint: As MAHA blows up over Supreme Court ruling limiting glyphosate litigation, Trump offers toothless plan to reduce pesticides in food
ChatGPT-Image-Mar-4-2026-09_39_03-AM
Transgender female athletes and Title IX: Separating ‘policy’ from ‘legality’
ChatGPT-Image-Jun-23-2026-12_19_35-PM
Ideological red flag: Led by anti-vax doctor, Tennessee is now the U.S. epicenter selling potent ivermectin shown worthless to prevent or treat Covid
Screenshot-2026-06-30-at-2.06.25-PM
PEW study: The sick state of American health information
ChatGPT-Image-Jun-25-2026-12_23_17-PM
No, Bill Gates did not secretly engineer ticks to promote veganism
Screenshot-2026-06-17-at-12.31.01-PM
Viewpoint: The dangerous influence of ‘woke’ post-modernism in science
marijuana-pot-in-hand-nveri-st-xpm-t-abq-fkifeos-s-rws-cmpx-
Facts & Fallacies podcast: Legalized weed drives drug addiction, psychosis?
photodune farming tractor s
Viewpoint: Glyphosate may be hazardous, but it is not dangerous as used by farmers. Critics of the Supreme Court’s Roundup ruling garble hazard with risk
ChatGPT-Image-Mar-10-2026-01_39_01-PM
Viewpoint—“Miracle molecule” debunked: Why acemannan supplements don’t work
Screenshot-2026-06-30-at-3.08.03-PM
From infrared sauna blankets to collagen gummies, here’s the top 10 social-media-promoted wellness shams
Screenshot-2026-06-30-at-10.43.50-AM
Viewpoint: Why are there no approved bioengineered insect-protected (Bt) apples?
ChatGPT-Image-Jun-25-2026-01_14_50-PM
Viewpoint: Disinformation grift: The wellness industry is a lucrative and mostly worthless marketplace of ‘balms, brews, and baloney’
Trans-flag
Explaining the Supreme Court ruling empowering states to ban transgender female athletes from competing in women’s sports
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.